Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MegaMOST biology-driven Phase II trial in advanced/metastatic tumors
2019-001494-88Phase 2Active
- Sponsor
- Centre Léon Bérard
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of siremadlin, ribociclib and cabozantinib in cancer (3 cohorts), sponsored by Centre Léon Bérard. Primary endpoint: Progression free rate after 3 months of treatment (3M-PFR). Started May 2019; status: active.
02
Drugs
siremadlinribociclibcabozantinib
03
Conditions
cancer
Beyond the preview
Go deeper on 2019-001494-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001494-88.